

AMENDMENTS

Please enter the following amendments:

IN THE SPECIFICATION

Page 12, line 19, please delete "heterogenous" and insert therefor --heterogeneous--.

IN THE CLAIMS:

Please cancel claims 4, 12-14, and 25-26, without prejudice to or disclaimer of the subject matter contained therein.

In claim 5, first line, please delete "4" and insert therefor --1--.

Please add the following claims:

--27. (NEW) The method of claim 1, wherein said marker is vascular endothelial growth factor mRNA.

28. (NEW) The method of claim 1, wherein said step of monitoring a marker is selected from the group consisting of spectrophotometrical determination after the addition of a specific chromogenic substrate, detection with antibodies, two stage clotting assay, one-stage recalcification assay, enzyme-linked immunosorbent assay, solid-phase enzyme immunoassay employing polyclonal antisera, hydrogen peroxide assay, and measurement of tissue factor mRNA levels in endothelial cells.

29. (NEW) The method of claim 1, wherein said efficacious dose is where additional amounts of the drug cause a downward slope of greater than 5% in said standard.

30. (NEW) The method of claim 1, wherein said efficacious dose is where additional amounts of the drug cause a change of less than 5% in the slope of said standard.

31. (NEW) The method of claim 1, wherein said efficacious dose is between a minimal and a maximal dose.